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Abstract
Background: Cytoplasmic inclusion bodies within hepatocytes may have different etiologies,
including the Endoplasmic Reticulum Storage Diseases (ERSDs). ERSD is a pathological condition
characterized by abnormal accumulation of proteins destined for secretion in the endoplasmic
reticulum of hepatocytes; it may be congenital (primary) or acquired (secondary). Fibrinogen
storage disease is a form of ERSD.
Case Presentation: We present a case of fibrinogen storage disease secondary to estrogen
replacement therapy. Its causal relationship to the drug is shown by histological,
immunohistochemical and ultrastructural studies of paired liver biopsies obtained during and after
the drug therapy.
Conclusion: The liver biopsies of patients with idiopathic liver enzyme abnormalities should be
carefully evaluated for cytoplasmic inclusion bodies and, although rare, fibrinogen deposits.
Background
Cytoplasmic inclusions in hepatocytes are encountered in
a wide range of clinical conditions including chronic hep-
atitis B, α1-antitrypsin deficiency, type IV glycogenosis,
Lafora's disease, fibrinogen storage disease, and in drug
reactions [1,2]. Endoplasmic Reticulum Storage Disease
(ERSD) of the liver is a pathological condition character-
ized by abnormal accumulation of proteins destined for
secretion in the endoplasmic reticulum. The term ERSD
encompasses α1-antitrypsin deficiency, the prototype dis-
order, plus fibrinogen storage disease and α1-antichymot-
rypsin deficiency [3]. ERSD can be congenital or acquired.
The congenital form is associated with the accumulation
of only one protein, due to its altered structure. The accu-
mulation is permanent and affects mainly the rough
endoplasmic reticulum (RER). The most common cause
of this condition is α1-antitrypsin deficiency. Acquired
[secondary] form occurs due to exogenous agents or in the
presence of concomitant diseases such as infections, and
therefore structurally normal proteins accumulate in sev-
eral cellular organelles.
In this article, we report a case of fibrinogen storage dis-
ease of the liver secondary to the use of oral contracep-
tives. This is the first reported case of fibrinogen storage
disease secondary to estrogen ingestion. Informed con-
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sent was obtained from the patient regarding her recruit-
ment in this case study.
Case presentation
A forty-year-old female was referred to our department for
evaluation of elevated liver enzymes in May, 2004. She
had no systemic symptoms. A year before, she had had a
total abdominal hysterectomy and bilateral salpingo-
oophorectomy. Since then, she had been on hormone
replacement therapy with estrogen. Six months ago, dur-
ing her routine follow-up, elevation of transaminase lev-
els was noted. This elevation persisted for the next 6
months. She was then referred to our department for fur-
ther investigation.
Laboratory features of the patient regarding this period are
shown in Table 1. Detailed questioning of the patient
revealed no history of past alcohol abuse. Screening for
viral antigens and for antibodies against them, as well as
screening for viral nucleotide-acid sequences (including
HCV-RNA/-cDNA PCR), found no evidence of infection.
Levels of auto-antibodies, serum transferrin saturation,
serum ferritin, serum ceruloplasmin, serum copper,
serum α1-antitrypsin, and 24-hour urinary copper excre-
tion were either negative or within normal limits. Abdom-
inal ultrasonography was unremarkable. Doppler
ultrasound imaging of portal and hepatic veins and the
hepatic artery revealed no thrombosis.
A liver biopsy was performed. Histopathological examina-
tion revealed focal necrosis and mild fibrotic activity.
Macrovesicular steatosis affecting 5% of hepatocytes, in
addition to several foci of prominent nuclear pleomor-
phism and hyperchromasia were also noted. However, the
most remarkable finding was the presence of abundant
intracytoplasmic, sharply bordered, pale eosinophilic
inclusions that exhibited a ground-glass appearance (Fig-
ure 1). Periodic acid-Schiff (PAS), diastase-treated PAS
and colloidal iron stains were applied. Immunohisto-
chemistry for hepatitis B surface (mouse monoclonal anti-
body clone: Tg, Neomarkers) and core (mouse
monoclonal antibody clone: Tordji-22, Signet) antigens,
α1-antitrypsin (rabbit antibody, Zymed), fibrinogen (rab-
bit anti-human antibody, Dako), α fetoprotein (rabbit
polyclonal antibody, Signet), complement 3 (mouse
monoclonal antibody clone: HAV 3–4, Dako) and com-
plement 4 (rabbit anti-human antibody, Dako) were per-
formed. A three-step streptavidin biotin method using
AEC as chromogen was applied in the immunohisto-
chemical procedure. The inclusions were negative to PAS
and colloidal iron. No reactivity with antibodies against
hepatitis antigens, α1-antitrypsin and complement 3 was
observed. Diffuse and strong positivity was observed for
fibrinogen in cytoplasmic inclusions (Figure 2). We also
detected less positivity for complement 4 and α-fetopro-
tein.
Paraffin-embedded tissue was processed for electron
microscopic examination. Ultrastructurally, the inclu-
sions were found to be moderately electron-dense, finely
granular, homogenous bodies that are encircled by mem-
branes, corresponding to a dilated endoplasmic reticulum
(Figure 3). There were no parallel arrays of tubular struc-
tures in the inclusions.
Serum fibrinogen level was within normal limits. We per-
formed tests for qualitative fibrinogen function. Pro-
thrombine time, partial thromboplastin time and
Intracytoplasmic inclusions with ground-glass appearance  affecting most of the hepatocytes in this area Figure 1
Intracytoplasmic inclusions with ground-glass appearance 
affecting most of the hepatocytes in this area. Mononuclear 
inflammatory infiltrate in a portal area is also seen. Hematox-
ylin-eosin, ×40. Inset: Higher magnification of this area, (H&E, 
×200).
Table 1: Laboratory features of the patient with exogenous 
estrogen
Laboratory parameter Result Normal range
Aspartate aminotransferase (IU/L) 565 0–40
Alanine aminotransferase (IU/L) 545 0–40
Lactate dehydrogenase (IU/L) 424 254–474
Alkaline phosphatase (IU/L) 354 112–330
gamma-glutamyltranspeptidase (IU/L) 98 0–50
Total bilirubin (mg/dl) 0.5 0.2–1.2
Blood urea nitrogen (mg/dl) 18 2–20
Creatinine (mg/dl) 0.4 0.4–1.0
Triglycerides (mg/dl) 154 29–180
Total cholesterol (mg/dl) 180 128–200
Blood glucose (mg/dl) 85 60–110
Blood ammonium-N (mg/dl) 11 40–85BMC Gastroenterology 2005, 5:36 http://www.biomedcentral.com/1471-230X/5/36
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thrombin time were also within normal limits. The
patient had no history of prolonged bleeding episodes,
menorrhagia, or epistaxis. Since infectious, auto-immune
or metabolic diseases were excluded, a drug effect was sus-
pected. Therefore, estrogen therapy was ceased and the
patient was followed monthly in order to check transam-
inase levels. Her serum transaminase levels decreased
gradually at each monthly visit and normalized at the
third month. Then we decided to perform a control liver
biopsy. Parenchymal and portal inflammation, steatosis
and necroinflammatory activity were remarkably reduced
in the second liver biopsy (Figure 4). Again, the same
staining procedures were applied. Compared to the first
biopsy, fibrinogen positive inclusions decreased dramati-
cally to the point where only one hepatocyte contained an
inclusion. Fibrotic activity and nuclear dysplastic findings
remained almost the same.
Conclusion
The patient had elevated transaminase levels without any
accompanying clinical symptoms. Her first liver biopsy
revealed cytoplasmic inclusion bodies within hepatocytes
associated with chronic hepatitis and mild fibrotic activ-
ity. The inclusions were sharply bordered and faintly eosi-
nophilic together with a ground-glass appearance. They
were negative to PAS and colloidal iron; therefore type IV
glycogenoses and Lafora's disease were ruled out on mor-
phological grounds, respectively. No staining with hepati-
tis antigens and α1-antitrypsin was observed
immunohistochemically. Diffuse and strong positivity for
fibrinogen was observed. Her serum fibrinogen levels, in
addition to prothrombin, partial thromboplastin and
thrombin times – excluding dysfibrinogenemia – were
within normal limits. The patient was not the offspring of
a consanguineous marriage.
Fibrinogen storage in hepatocytes has been previously
reported in patients with or without hypofibrinogenemia.
The disease was first shown in German families as a famil-
ial hypofibrinogenemia [4,5]. Later, specific mutations in
hereditary cases were reported [6,7]. Callea et al., placed
fibrinogen storage disorders in the ERSD group along with
α1-antitrypsin and α1-antichymotrypsin deficiencies, and
proposed a classification of fibrinogen storage diseases
based on morphologic and clinical evidence, and thus
divided the entity into three types [3]. In type I, the inclu-
sions are defined as round or polygonal, weakly eosi-
nophilic cytoplasmic deposits with irregular borders. This
type is a hereditary hypofibrinogenemia, genetically char-
acterized by the presence of mutant variants of the fibrin-
ogen molecule, namely fibrinogen Brescia and fibrinogen
Aguadilla [3,6,7]. The other two types are rarer. Type II
inclusions are large, hyaline bodies that occupy the entire
cytoplasm and result in a ground-glass appearance, while
round, eosinophilic globules surrounded by a clear halo
constitute the inclusions of type III. At the ultrastructural
level, type I inclusions are characterized by the presence of
densely packed tubular structures, arranged in curved
bundles resulting in a finger-print-like appearance. Type II
inclusions appear as granular or fragmented fibrillar
material and type III inclusions contain a central core
resembling the tubular structures of Type I and a sur-
rounding similar to that of Type II. In all types, the inclu-
sions correspond to dilated cisternae of RER.
On ultrastructure, inclusions appear as finely granular, homo- geneous material bounded by membranes (arrows) Figure 3
On ultrastructure, inclusions appear as finely granular, homo-
geneous material bounded by membranes (arrows). ×4400
Strong and diffuse immunohistochemical positivity of the  inclusions for fibrinogen, ×40 Figure 2
Strong and diffuse immunohistochemical positivity of the 
inclusions for fibrinogen, ×40. İnset: Same area with higher 
magnification. (×200).BMC Gastroenterology 2005, 5:36 http://www.biomedcentral.com/1471-230X/5/36
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Cases of fibrinogen storage disease without hypofibrino-
genemia have been recently reported. One such patient
had atypical type of cytoplasmic inclusions and was con-
sidered to demonstrate a congenital case [8]. Two other
patients revealed fibrinogen storage in the liver during an
acute infectious episode together with Type II inclusions.
The latter were thought to have transient, acquired forms
of the disease [9].
The inclusions observed in our patient were large, hyaline
bodies occupying the entire cytoplasm, resulting in a
ground-glass appearance. This morphology is consistent
with Type II inclusions. Neither the characteristics of Type
I inclusions, such as irregular borders, a clear halo sur-
rounding the inclusion or an acicular shape, nor the find-
ings consistent with Type III inclusions [round,
eosinophilic globules with a clear halo around] were
present in our patient. Electron microscopy revealed
homogenous, granular material within dilated ER, which
are also the characteristics of Type II inclusions. Tubular
structures found in Type I and partially in Type III inclu-
sions were not present either. These findings allowed us to
consider the patient's inclusions to be Type II.
In the first biopsy, fibrinogen storage was accompanied
with accumulation of complement 4 and α fetoprotein.
This simultaneous deposition of multiple proteins des-
tined for secretion indicates a dysfunction in the secretory
apparatus, rather than the retention of a single mutant
protein [10]. Callea et al., claimed that this finding may
help distinguish between the acquired and congenital
forms of the disease [3]. A single, genetically abnormal
protein cannot be translocated from RER to smooth endo-
plasmic reticulum (SER), therefore it accumulates in RER
[11]. This type of selective and exclusive retention of
fibrinogen defines the congenital and the more frequent
form of the disease. On the other hand, structurally nor-
mal proteins can get trapped in RER, SER and/or secretory
vesicles due to a secretory dysfunction, which might be
caused by exogenous agents like alcohol, and by drugs
such as colchicine [3]. Thus in our case, a drug-induced,
acquired form of fibrinogen storage is further supported
by the above findings as well as the dramatic resolution of
histopathologic and biochemical parameters after cessa-
tion of estrogen administration.
We ascribed the findings of chronic hepatitis and mild
fibrotic activity in our patient to fibrinogen storage.
Indeed, cases without hypofibrinogenemia, as well as
those with hereditary hypofibrinogenemia and those that
have a mutational basis, were shown to develop chronic
hepatitis, fibrosis or cirrhosis, in the literature [3,4,8,9].
Importantly, low levels of fibrinogen does not necessarily
accompany the hepatic storage of fibrinogen, which was
the case in our patient. This may also support the second-
ary, acquired nature of the disease.
Relying on the results explained above, we conclude that,
in our patient an oral regimen of estrogen is associated
with fibrinogen storage disorder. To our knowledge, this
is the first case reported to date to show hepatic fibrinogen
storage secondary to estrogen ingestion. The liver biopsies
of patients with idiopathic liver enzyme abnormalities
should be carefully evaluated for cytoplasmic inclusion
bodies and, although rare, fibrinogen deposits.
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